Profile data is unavailable for this security.
About the company
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.
- Revenue in USD (TTM)12.95m
- Net income in USD-51.36m
- Incorporated2005
- Employees65.00
- LocationAssembly Biosciences IncTwo Tower Place, 7Th FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (212) 554-4388
- Fax+1 (646) 706-5101
- Websitehttps://www.assemblybio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elutia Inc | 25.05m | -49.46m | 79.14m | 54.00 | -- | -- | -- | 3.16 | -2.35 | -2.34 | 1.24 | -2.07 | 0.5219 | 2.06 | 4.27 | 463,833.30 | -103.05 | -42.93 | -599.50 | -79.34 | 42.01 | 43.32 | -197.48 | -64.16 | 0.5499 | -1.36 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Serina Therapeutics Inc | 137.00k | -20.96m | 79.17m | 4.00 | -- | -- | -- | 577.92 | -14.07 | -14.07 | 0.0909 | -0.5121 | 0.0117 | -- | 3.86 | 34,250.00 | -179.27 | -194.46 | -- | -- | 67.88 | 85.80 | -15,301.46 | -2,347.36 | -- | -0.9274 | 1.70 | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| Cue Biopharma Inc | 7.02m | -49.97m | 79.29m | 53.00 | -- | 2.64 | -- | 11.29 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -55.09m | 79.89m | 47.00 | -- | 2.00 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7498 | 0.00 | -- | -- | 0.00 | -53.21 | -48.44 | -56.51 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.5592 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Angion Biomedica Corp | 0.00 | -38.99m | 81.14m | 32.00 | -- | 16.58 | -- | -- | -6.63 | -6.63 | 0.00 | 0.4765 | 0.00 | -- | -- | 0.00 | -117.72 | -105.91 | -133.85 | -331.69 | -- | -- | -- | -712.81 | -- | -- | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Sellas Life Sciences Group Inc | 0.00 | -35.81m | 81.43m | 16.00 | -- | 8.19 | -- | -- | -1.12 | -1.12 | 0.00 | 0.1721 | 0.00 | -- | -- | 0.00 | -133.77 | -111.48 | -303.59 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Assembly Biosciences Inc | 12.95m | -51.36m | 83.53m | 65.00 | -- | 2.55 | -- | 6.45 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Gritstone bio Inc | 15.65m | -144.89m | 84.00m | 231.00 | -- | 5.44 | -- | 5.37 | -1.57 | -1.57 | 0.17 | 0.1423 | 0.0901 | -- | 40.53 | 67,727.27 | -83.47 | -48.08 | -97.70 | -55.18 | -- | -- | -926.13 | -573.71 | -- | -554.88 | 0.7428 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Ikena Oncology Inc | 3.85m | -70.09m | 85.42m | 34.00 | -- | 0.5499 | -- | 22.20 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Chimerix Inc | 41.00k | -82.59m | 86.65m | 72.00 | -- | 0.4977 | -- | 2,113.52 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Allovir Inc | 0.00 | -179.53m | 86.82m | 112.00 | -- | 0.7201 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 194.77k | 3.55% |
| Millennium Management LLCas of 31 Mar 2024 | 124.92k | 2.28% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 72.72k | 1.33% |
| Geode Capital Management LLCas of 31 Mar 2024 | 52.20k | 0.95% |
| Acuitas Investments LLCas of 31 Mar 2024 | 49.73k | 0.91% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 39.46k | 0.72% |
| Federated MDTA LLCas of 31 Mar 2024 | 25.39k | 0.46% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 14.50k | 0.26% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 12.11k | 0.22% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 11.32k | 0.21% |
